<DOC>
	<DOCNO>NCT00004940</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine long-term efficacy safety L-cysteine prevention photosensitivity patient erythropoietic protoporphyria .</brief_summary>
	<brief_title>Phase III Study L-Cysteine Patients With Erythropoietic Protoporphyria</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This phase III study , last 3 year ; 1996-1999 . Patients administer L-cysteine orally twice daily , 2 capsule breakfast 2 lunch . Patients fill questionnaire diary sheet reaction sunlight exposure , blood test 3 time year . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Protoporphyria , Erythropoietic</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Erythropoietic protoporphyria RBC protoporphyrin great 50 micrograms/100 dL Prior/Concurrent Therapy At least 3 month since prior betacarotene Lcysteine No concurrent betacarotene Patient Characteristics Fertile female patient must use effective contraception duration trial 3 week thereafter Not pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>erythropoietic protoporphyria</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>porphyria</keyword>
	<keyword>rare disease</keyword>
</DOC>